Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Mol Cancer Res. 2022 Mar 1;20(3):373–386. doi: 10.1158/1541-7786.MCR-21-0208

Figure 6. A highly specific, next-generation small molecule inhibitor of MALT1 is effective at abrogating migration and invasion of GPCR+ breast cancer cells.

Figure 6.

A and B, Effect of MLT-748 on migration of BT549 (A) and MDA-MB-231 (B) cells in the scratch wound assay. Quantification of scratch would closure is plotted as a continuous function of time (mean ± SD, n=8–10), ***, P < 0.001, two-way ANOVA. C, Effect of MLT-748 on BT549 and MDA-MB-231 cell invasiveness, as measured using matrigel-coated Boyden chambers. Representative images of invaded cells are shown at left. Quantification of cell invasion is shown at right (mean ± SEM, n=12), ****, P < 0.0001, two-tailed t test with Welch’s correction. D, Effect of MLT-748 on MALT1-dependent CYLD cleavage in BT549 and MDA-MB-231 cells. Cells were treated ± a single dose of 20 μM MLT-748 for 5 days before harvesting and immunoblot analysis.